new_0222_0720|CMMB|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|price_next_month|price_second_month
new_0222_0720|CMMB|1|Chemomab Therapeutics Ltd Total Current Assets (Quarterly) (USD)|Chemomab Therapeutics Ltd Cash and Short Term Investments (Quarterly) (USD)|Chemomab Therapeutics Ltd Inventories (Quarterly) (USD)|Chemomab Therapeutics Ltd Net PP&E (Quarterly) (USD)|Chemomab Therapeutics Ltd Goodwill and Intangibles (Quarterly) (USD)|Chemomab Therapeutics Ltd Total Liabilities (Quarterly) (USD)|Chemomab Therapeutics Ltd Total Current Liabilities (Quarterly) (USD)|Chemomab Therapeutics Ltd Total Long Term Liabilities (Quarterly) (USD)|Chemomab Therapeutics Ltd Total Deposits (Quarterly) (USD)|Chemomab Therapeutics Ltd Book Value (Quarterly) (USD)|Chemomab Therapeutics Ltd Retained Earnings (Quarterly) (USD)|Chemomab Therapeutics Ltd Treasury Stock (Quarterly) (USD)|Chemomab Therapeutics Ltd EV to Revenues|Chemomab Therapeutics Ltd EV to Earnings|Chemomab Therapeutics Ltd EV to Free Cash Flow|Chemomab Therapeutics Ltd EV to Assets (Quarterly)|Chemomab Therapeutics Ltd PS Ratio|Chemomab Therapeutics Ltd PE Ratio|Chemomab Therapeutics Ltd Price to Book Value|Chemomab Therapeutics Ltd PEG Ratio|Chemomab Therapeutics Ltd Debt to Equity Ratio|Chemomab Therapeutics Ltd Dividend Yield|Chemomab Therapeutics Ltd Shareholder Yield (TTM)|Chemomab Therapeutics Ltd Percent of Shares Outstanding Short|Chemomab Therapeutics Ltd Total Receivables (Quarterly) (USD)|Chemomab Therapeutics Ltd Total Payables (Quarterly) (USD)|Chemomab Therapeutics Ltd Total Capital Stock (Quarterly) (USD)|Chemomab Therapeutics Ltd Return on Invested Capital|Chemomab Therapeutics Ltd Quality Ratio Score|Chemomab Therapeutics Ltd Momentum Score|Chemomab Therapeutics Ltd Beta (1Y)|Chemomab Therapeutics Ltd Sustainable Growth Rate (TTM)|Chemomab Therapeutics Ltd Institutional Investor Ownership Percentage|Chemomab Therapeutics Ltd Average Diluted Shares Outstanding (Quarterly)|Chemomab Therapeutics Ltd Total Employees (Annual)|Chemomab Therapeutics Ltd EPS Diluted (Quarterly) (USD)|Chemomab Therapeutics Ltd Shares Outstanding|Chemomab Therapeutics Ltd Repurchase of Capital Stock (Quarterly) (USD)|Chemomab Therapeutics Ltd Ordinary Shares Number (Quarterly)|Chemomab Therapeutics Ltd Payout Ratio|Chemomab Therapeutics Ltd Quick Ratio (Quarterly)|Chemomab Therapeutics Ltd Normalized Diluted EPS (Quarterly) (USD)|Chemomab Therapeutics Ltd Stock Buybacks (Quarterly) (USD)|Chemomab Therapeutics Ltd Effective Tax Rate (TTM)|Chemomab Therapeutics Ltd Return on Equity|Chemomab Therapeutics Ltd Net Income (TTM) (USD)|Chemomab Therapeutics Ltd Revenue (TTM) (USD)|Chemomab Therapeutics Ltd Dividend Per Share (Quarterly) (USD)|Chemomab Therapeutics Ltd Revenue (Quarterly) (USD)|Chemomab Therapeutics Ltd Gross Profit (Quarterly) (USD)|Chemomab Therapeutics Ltd SG&A Expense (Quarterly) (USD)|Chemomab Therapeutics Ltd Pre-Tax Income (Quarterly) (USD)|Chemomab Therapeutics Ltd Net Income (Quarterly) (USD)|Chemomab Therapeutics Ltd Net Interest Income (Quarterly) (USD)|Chemomab Therapeutics Ltd Price (USD)|Chemomab Therapeutics Ltd Total Return Price (USD)|Chemomab Therapeutics Ltd Enterprise Value (USD)|Chemomab Therapeutics Ltd 30-Day Average Daily Volume|Chemomab Therapeutics Ltd 1 Year Price Returns (Daily)||
new_0222_0720|CMMB|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric||
new_0222_0720|CMMB|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily||
new_0222_0720|CMMB|5|91.5|91.5|0|91.5|0|91.5|91.5|91.5|0|91.5|91.5|0|0|0|1.43352601156|0|0|0|1.43103448276|0|0|1.44678055191|0|15.3333333333|91.5|91.5|91.5|0|0|31.9523809524|30.5217391304|0|30.7142857143|109.6|0|109.6|37.75|0|91.5|0|0|109.6|109.6|0|0|91.5|0|0|0|0|109.6|109.6|109.6|109.6|6.9746835443|6.9746835443|1.43352601156|6.96710526316|1.44597249509||
new_0222_0720|CMMB|6|2|2|0|2|0|2|2|2|0|2|2|0|0|0|173|0|0|0|174|0|0|761|0|15|2|2|2|0|0|21|23|0|7|5|0|5|4|0|2|0|0|5|5|0|0|2|0|0|0|0|5|5|5|5|158|158|173|152|509||
new_0222_0720|CMMB|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily||
new_0222_0720|CMMB|201812||||||||||||||||||||||0|||||||||||||||||||||||||||||||||131.2|131.2|||||
new_0222_0720|CMMB|201903||||||||||||||||||||||0|||||||||||||||||||||||||||||||||108|108||2608.9||93.2|76.7264
new_0222_0720|CMMB|201906||||||||||||||||||||||0|||||||||||||||||||||||||||||||||68|68||318.7667||50.48|36.6384
new_0222_0720|CMMB|201909||||||||||||||||||||||0|||||||||||||||||||||||||||||||||42.56|42.56||3599.0333||35.52|21.2192
new_0222_0720|CMMB|201912||||||||||||||||||||||0|||||||||0.6736||||||||||||||||||||||||22.4|22.4||2272.2333|-88.7688|21.6|19.5872
new_0222_0720|CMMB|202003||||||||||||||||||||||0||||||||1|0.2754|||11.0029||-0.154||||||-0.154|0||||||||0.152|-1.695|-1.695|0.009|12.576|12.576||1599.6667|-88.4327|12.8|18.24
new_0222_0720|CMMB|202006||||||||||||||||||||||0||||||||1|1.4254|||11.0029||-0.0982||||||-0.0982|-3||||||||0.254|-1.081|-1.081|0.02|21.92|21.92||5837.5|-69.4196|14.528|16.8
new_0222_0720|CMMB|202009||||||||||||||||||||||0||||||||2|0.8363|||11.0029||-0.1112||||||-0.1112|0||||||||0.194|-1.224|-1.224|0.001|19.04|19.04||3181.9|-50.4197|18.88|24
new_0222_0720|CMMB|202012||11.698||||1.674||||||||||||||||0||||||||7|1.0977|||||-0.1773|||||||-0.5|||-5.951|||||0.688||-1.951||32|32||208831.3333|23.5714|38.24|60.16
new_0222_0720|CMMB|202103|59.523|58.203||0.545||4.959|4.631|0.328||55.164|-25.399|||||||||||0|||0.32|2.083|0|||9|-0.8276|||7.8376||-0.22|||227.9561|||-0.22|-45.372|||-5.96|||||0.542|-1.704|-1.704|-0.005|28.78|28.78||211092.8667|128.292|34.26|16.07
new_0222_0720|CMMB|202106|68.835|66.92||0.635||2.479|2.159|0.32||68.039|-28.169||||-17.0186||||4.0171|||0||0.1911|1.915|0.472|0|||2|-0.8017||32.5897|10.8133||-0.26|11.3978||227.9561|||-0.26|-13.428|||-7.649|||||1.446|-2.77|-2.77|-0.017|19.21|19.21|153.1627|533865.2333|-13.2299|16.31|14.67
new_0222_0720|CMMB|202109|65.842|64.268||0.593||1.928|1.63|0.298||65.512|-31.137||||-5.9033||||2.0018|||0||0.1761|1.574|0.481|0|||3|1.2853||29.9484|11.3978||-0.26|11.3978||227.9561|||-0.26|0.072|||-9.393|||||1.404|-2.968|-2.968|-0.077|11.95|11.95|69.2837|107698.9667|-39.2544|9.81|9.25
new_0222_0720|CMMB|202112||61.161||||2.887|||||||||-1.3704||||1.2269|||0||0.236||||||1|0.0936||29.9698|||-0.44|11.4045||||||0.091|||-12.478|||||2.641||-5.036||7.05|7.05|16.1076|168249.9667|-75.0723|5.22|3.7285
new_0222_0720|CMMB|202203||57.406||||3.72|||||||||||||0.9017|||||||||||||||||-0.44|11.4045|||||||||-15.878|||||2.575||-5.104||4.86|4.86|-5.7351|82394.5||3.14|3.08
new_0222_0720|CMMB|202206||51.724||||4.542|||||||||||||0.8159|||||||||||||||||-0.54|11.4317|||||||||-19.298|||||3.34||-6.19||4.095|4.095|-9.4267|43038.7333||3.03|3.27
new_0222_0720|CMMB|202209||46.466||||5.595|||||||||||||0.5205|||||||||||||||||-0.7|11.4508|||||||||-24.41|||||2.894||-8.08||2.36|2.36|-24.1736|33034.6||2.02|2.04
new_0222_0720|CMMB|202212||39.893||||6.84|||||||||||||0.6043|||||||||||||||||-0.72|11.0498||||||0.951|||-27.646|||||2.747||-8.272||2.3395|2.3395|-9.5841|75548.6333||2.3|1.55
new_0222_0720|CMMB|202303||32.706||||7.059|||||||||||||0.4881|||||||||||||||||-0.8|11.0498|||||||||-31.295|||||2.162||-8.753||1.6|1.6|-15.1368|960663.5||1.55|1.58
new_0222_0720|CMMB|202306||26.589||||6.858|||||||||||||0.5099|||||||||||||||||-0.72|11.8209||||||-1.368|||-33.075|||||3.175||-7.97||1.29|1.29|-18.4518|340608.7||1.34|1.11
new_0222_0720|CMMB|202309|||||||||||||||||||0.4892|||||||||||||||||-0.34|11.8227|||||||||-29.076|||||0.99||-4.081||0.91|0.91|-15.832|17118.2667||0.82|0.5597
new_0222_0720|CMMB|202312||19.784||||5.154|||||||||||||0.261|||||||||||||||||-0.22|14.2047|||||||||-24.221|||||0.751||-3.417||0.51|0.51|-20.6252|2866032.9333||0.58|0.6777
new_0222_0720|CMMB|202403||15.877||||4.678|||||||||||||0.626|||||||||||||||||-0.28|14.219|||||||||-19.336|||||0.896||-3.868||0.749|0.749|-8.8464|420943.8||0.7|0.9088
new_0222_0720|CMMB|202406||12.727||||4.559|||||||||||||1.0927|||||||||||||||||-0.26|14.3592|||||||||-14.997|||||0.84||-3.631||1.0245|1.0245|-2.0703|100862.1||1.21|1.65
new_0222_0720|CMMB|202409||19.378||||4.579|||||||||||||2.9101|||||||||||||||||-0.2|18.8566|||||||||-14.399|||||0.874||-3.483||1.57|1.57|15.7755|341699.5333||1.44|1.59
new_0222_0720|CMMB|202412||14.266||||3.427|||||||||||||2.5213|||||||||||||||||-0.16|18.8566|||||||||-13.945|||||0.802||-2.963||1.81|1.81|18.5238|106908.8667||2.09|1.55
new_0222_0720|CMMB|202503||10.563||||2.426|||||||||||||1.588|||||||||||||||||-0.14|18.8628|||||||||-13.4|||||0.994||-3.323||1.14|1.14|7.042|646035.3667||1.28|1.4
new_0222_0720|CMMB|202506|||||||||||||||||||2.1779||||||||||||||||||||||||||||||||||||1.2|1.2|12.0724|186179.3667||1.16|